Glenmark Pharma to Launch Sodium Phosphates Injection in US

Glenmark Pharmaceuticals has unveiled plans to introduce Sodium Phosphates Injection in the US market, with distribution scheduled to commence in April 2026. This launch marks another milestone in the company’s efforts to expand its generics portfolio and enhance its footprint in the highly competitive American pharmaceutical sector.

Key Highlights

• Product Launch: Sodium Phosphates Injection to be introduced in the US.
• Distribution Timeline: Rollout begins in April 2026.
• Strategic Expansion: Strengthens Glenmark’s injectable portfolio in the US generics market.
• Market Impact: Expected to boost accessibility of affordable, quality medicines.
• Global Outlook: Reinforces Glenmark’s commitment to expanding its international presence.

The launch of Sodium Phosphates Injection aligns with Glenmark’s broader strategy of diversifying its product offerings and tapping into high-demand therapeutic segments. With the US being one of the largest pharmaceutical markets globally, this move is expected to enhance revenue streams and strengthen the company’s competitive positioning.

Source: Glenmark Pharmaceuticals corporate announcement